Invion ( (AU:IVX) ) just unveiled an update.
Invion Limited has expanded its collaboration with South Korean pharmaceutical group Hanlim to include oesophageal cancer in its development program for the cancer drug candidate INV043. This partnership, which initially focused on glioblastoma, will see Hanlim funding studies while Invion retains rights to the Photosoft™ technology and any new intellectual property. The collaboration aims to address the high unmet need for oesophageal cancer treatments, leveraging Hanlim’s resources and expertise. The global market for oesophageal cancer is projected to grow significantly, enhancing Invion’s industry positioning and offering potential new therapeutic options for high-need cancers.
More about Invion
Invion is a life-science company specializing in the global research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing rights in Australia, New Zealand, and parts of Asia for cancer indications, and in Asia and Oceania for atherosclerosis and infectious diseases. Invion is listed on the ASX.
Average Trading Volume: 110
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.36M
See more data about IVX stock on TipRanks’ Stock Analysis page.